We’re

/vairˈoo/

Veru Inc. is an oncology and urology biopharmaceutical company developing and commercializing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals .

PHARMACEUTICALS

VERU-111

VERU-111

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

LEARN MORE

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

LEARN MORE

VERU-100

VERU-100

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

LEARN MORE

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

TADFIN® combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

LEARN MORE

LATEST NEWS

Jefferies 2019 Healthcare Conference

June 4, 2019

Watch the replay of the webcast of our presentation at the Jefferies 2019 Healthcare Conference.

Veru presents at the Jefferies Healthcare Conference on June 4, 2019

News Releases Sorted By Date